Kornimate/medical-research-clean huggingface dataset:
robotic assisted hand rehabilitation outcomes in adults after covid-19

Conditions: Robotic Exoskeleton; Post-acute Covid-19 Syndrome; Rehabilitation Outcome; Physical And Rehabilitation Medicine

Summary: prolonged hospitalization in severe covid-19 cases can lead to substantial muscle loss and functional deterioration. while rehabilitation is vital, conventional approaches encounter capacity constraints. therefore, assessing the efficacy of robotic-assisted rehabilitation is crucial for post-covid-19 fatigue syndrome patients, aiming to improve motor function and overall recovery. the study focuses on evaluating rehabilitation effectiveness in individuals with upper-extremity impairment using a hand exoskeleton-based robotic system.


Eligibility criteria:
inclusion criteria: * over 30 years old * patients infected with covid-19 and has received care at the centro hospitalario benito menni * patients with acute or limited functional or strength impairment in at least one of the upper extremities * patients who would complete a rehabilitation program and a series of patient reported outcome questionnaires and a follow up evaluation * patients who give inform written consent. exclusion criteria: * presence of behavioral disorders * dementia (loss of memory of cognitive functions) * disorders of consciousness (confusional states and drowsiness) * uncontrolled or severely limiting delusions and hallucinations * infectious skin diseases * rrisk of epileptic seizures due to covid itself or prior to it * severe visual impairments * severe spasticity with a modified ashworth scale \>2, joint stiffness in the wrist and fingers * pain with a score \>8 on the visual analog scale (vas) during mobilization of the affected hand.
clinical trial for the evaluation of customized 3d printed niv nasal masks in premature infants

Conditions: Premature Lungs

Summary: clinical trial with crossed groups, open, masked for the evaluation of the main outcome. inclusion of all premature infants with a birth weight less than 1500 g requiring non-invasive ventilation (niv). premature will be randomised to start alternatively with mt or 3dm. each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. the study period will be a maximum of 7 days. to compare the time in which preterm maintain sato2 below 85% with the 3dm versus the traditional mask (tm) in preterm \< 1500 g. other secondary objectives regarding ventilation enhancement will be assessed, such as the number of bradycardias, cardiorespiratory arrest and need for resuscitation in the context of apnea. also, skin lesions of the nose resulting from the pressure applied by any of the masks (tm or 3dm) and the need for analgesia and/or sedation for pain control or discomfort will be assessed. parental perception and satisfaction will be assessed.

improvement and optimization of non-invasive ventilation (niv) in preterm and low birth weight infants is essential in order to reduce morbidity. by the use of 3d printing design (3dm), these infants would be provided with customized nasal masks, according to their particular anatomical features while on niv. this would lead to a greater stabilization of the respiratory system, decreased apnea spells, oxygen desaturation and bradycardia, less need for intubation and less skin nose injury, all of which might improve neurodevelopmental outcomes.

Eligibility criteria:
inclusion criteria: * newborn prematurity * age: less than 30 days of life * required respiratory support with non-invasive ventilation (niv) * premature infant has not been on niv for more than 3 days before being included in the trial. * signature of the informed consent (ic) exclusion criteria: * failure to meet entry criteria * cyanotic congenital heart disease diagnosis * presence of serious malformations * presence of airway malformations

Keywords: neonatology nasal mask 3d printing additive manufacturing newborn premature prematurity neonate non-invasive ventilation (niv) oxygen saturation solidworks 3d scanner customized device continuous positive airway pressure (cpap)
ultra-high density mapping with multielectrode catheter vs conventional point by point mapping for ventricular tachycardia substrate ablation

Conditions: Ventricular Tachycardia

Summary: ultra-high density mapping with multielectrode catheter may improve slow conduction channels identification in ventricular tachycardia substrate ablation procedures compared to conventional point by point mapping. this study compares the ability of both mapping catheters to detect slow conduction channels in areas of myocardial scar and their utility to assess substrate modification after ablation.

this is a prospective, randomized controlled study. twenty patients with sustained ventricular tachycardia and structurally abnormal ventricle(s) will be prospectively enrolled. in all patients a detailed pre and post-ablation electroanatomical mapping will be performed, and these maps will be merged with ct and/or mri images. patients will be randomly assigned to two groups. in group a patients both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a navistar thermocool catheter, and secondly by multielectrode contact mapping using a pentaray catheter. in this group, target ablation sites will be guided by point by point map. in group b patients, both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a pentaray catheter, and secondly by conventional point by point mapping using a navistar thermocool catheter. in this group target ablation sites will be guided by multielectrode contact mapping. slow conduction channels will be identified by color-coded voltage map adjustment of the lower and upper thresholds and also the presence of fractioned electrograms with the delayed component showing sequential orthodromic activation. the entrances of these channels will be the target of the ablation sites (scar dechanneling technique).

Eligibility criteria:
inclusion criteria: * patients with indication for ventricular tachycardia substrate ablation. exclusion criteria: * pregnant woman. * reduced expectancy of life (less than 12 months) * patient participating in another clinical study that investigates a drug or device * psychologically unstable patient or denies to give informed consent * any cause that contraindicate ablation procedure or antiarrhythmic drug
nutritional status assessment in the elderly suffering from cancer : a national cross-ucog survey

Conditions: Malnutrition; Cancer; Elderly

Summary: protein-energy malnutrition (pem) is a frequent condition in patients suffering from cancer, especially the elderly. according to some studies, this malnutrition has important consequences in this population, by increasing the risk of treatment toxicities, premature interruption of chemotherapy, mortality and risks of complications. identifying cases of malnutrition is an objective pursued by the national nutrition and health programme and an important task of the "unités de coordination en oncogériatrie". the main goal of this study is to assess the loss of weight over the 6 month-period preceding the cancer treatment, regardless of kind (chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiation therapy, surgery, comfort care), in the elderly suffering from cancer.


Eligibility criteria:
inclusion criteria: * over 70 years of age * suffering from cancer * waiting for a treatment decision (whatever it is) * hospitalized in a hospital or come to consult in a hospital during the period of inclusion (2 periods of 6 weeks for two consecutive years) * affiliated to a social security system exclusion criteria: * patient unable to receive information regarding the study and/or provide its non objection regarding the use of its data * patient under tutorship or curatorship, deprived of freedom or placed under judicial protection

Keywords: malnutrition cancer elderly
bone marrow-derived stem cell transfer in acute myocardial infarctions

Conditions: Myocardial Infarction

Summary: the benefit of reperfusion therapies for st-elevation acute myocardial infarction (stemi) is limited by postinfarction left ventricular (lv) dysfunction.the purpose of this study is to determine whether intracoronary transfer of bone marrow cells will augment left ventricular function recovery of the heart.

despite early coronary reperfusion, salvage of ischemic myocardium is incomplete and loss of viable myocardium initiates a process of adverse left ventricular (lv) remodeling1, compromising clinical outcome. experimental data have suggested that autologous bone marrow-derived or circulating progenitor cells may be beneficial for lv function recovery, but underlying mechanisms are unclear and prominent cardiomyocyte transdifferentiation has only been reported under selected experimental conditions. early non-randomized clinical investigations indicate feasibility, safety and enhanced functional recovery after autologous human bone marrow-derived stem cell (bmsc) infusion into the infarct-related artery. more recently, a randomized open study demonstrated improvement of lv systolic function but not of lv remodeling following bmsc transfer. in the absence of trials, in which the control group reproduces the exact conditions of the cell transfer group, including bone marrow aspiration and a placebo intracoronary injection, the true benefit of cell transfer cannot be fully appreciated. we, therefore, designed a randomized, double-blind, and placebo-controlled exploratory study to investigate the effect of autologous bmsc transfer on lv functional and structural recovery after myocardial infarction. in view of the exploratory nature of the study and to detect potential mechanisms for the biological effect, we also assessed myocardial perfusion and oxidative metabolism using serial 1-\[11c\]acetate positron emission tomography (pet).

Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction with cumulative st-segment elevation \>=6mm, successful epicardial reperfusion after pci and significant lv dysfunction exclusion criteria: * patients presenting within 2 hours of symptom onset (no dilution of any treatment effect from aborted infarctions) * patients with prior coronary artery bypass grafting, pulmonary edema, cardiogenic shock or significant co-morbidities

Keywords: bone marrow cell transfer acute myocardial infarction left ventricular function
the use of oral naloxone to prevent post spinal fusion ileus

Conditions: Ileus; Fusion of Spine

Summary: postoperative ileus and opioid induced constipation are well-known post-operative complications. previously, research has shown that using peripherally acting opioid antagonists can help alleviate the condition. there has not been a prospective study to investigate whether use of peripherally acting opioid antagonists are effective in preventing post-operative ileus in patients having spinal fusion surgeries.

post operative ileus is a well-known complication following spinal fusion surgery. there has been some literature to demonstrate the safety and efficacy of oral naloxone to decrease the time to bowel movements after gastrointestinal surgery, to date, there have been no studies within the spine fusion literature to investigate oral naloxone's effects on the time to bowel movements. the aim of the present study is to use the previously established protocols and doses established in the gastrointestinal literature to see whether oral naloxone can decrease the time to first bowel movements.

Eligibility criteria:
inclusion criteria: * patients will be included if they are having an in-patient spinal fusion procedure, are 18 years or older, post and post-operative pain control plan includes opioid medications. exclusion criteria: * pregnancy, age \< 18, nursing, or documented allergy to naloxone

Keywords: ileus fusion of spine
effect of consuming oat bran mixed in water before a meal on glycemic responses in healthy humans - a pilot study

Conditions: Glucose Intolerance

Summary: viscous dietary fibers including oat β-glucan are one of the most effective classes of functional food ingredients for reducing postprandial blood glucose. the mechanism of action is thought to be via an increase in viscosity of the stomach contents that delays gastric emptying and reduces mixing of food with digestive enzymes, which, in turn, retards glucose absorption. previous studies suggest that taking viscous fibers separate from a meal may not be effective in reducing postprandial glycemia. the purpose of this study is to re-assess the effect of consuming a preload of a commercially available oat-bran (4.5, 13.6 or 27.3 g) containing 22% of high molecular weight oat β-glucan (o22) mixed in water before a test-meal of white bread on glycemic responses in 10 healthy humans.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * pregnancy * diabetes * recent medical or surgical hospitalization * use of drugs influencing glucose metabolism * use of drugs influencing gastrointestinal function * allergy to oats or wheat

Keywords: humans glycemic response oat beta-glucan
an observational study of radial access embolization procedures using hydropearl microspheres

Conditions: Uterine Fibroid; Arteriovenous Malformations; Hypervascular Tumors; Benign Prostatic Hyperplasia

Summary: this registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing hydropearl embolization procedures via radial access.


Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years old 2. subject is scheduled for a procedure for treatment with hydropearl microspheres using radial access. 3. subject is willing and able to complete follow-up requirements 4. subject is willing and able to sign a written informed consent form prior to participating in the registry. exclusion criteria: 1. unable to have a procedure with radial access for any reason. 2. participating in another clinical study which, in the opinion of the investigator, could impact the results of this registry. 3. pregnant or planning to become pregnant during the study.
transforming growth factor beta signalling in the development of muscle weakness in pulmonary arterial hypertension

Conditions: Muscle Weakness; Pulmonary Arterial Hypertension

Summary: pulmonary arterial hypertension (pah) is a disease that causes raised blood pressure in blood vessels that pick up oxygen from the lungs. it has a life expectancy similar to some cancers. there is treatment available but there is no cure. we now know that pah is associated with weakness in the muscles in the legs, which contributes to the symptoms patients' experience. researchers believe that certain proteins found in high levels in the blood of patients with other chronic diseases can affect muscle function and growth. one of these proteins is called growth differentiating factor (gdf) 8, high levels of which are associated with muscle weakness in chronic obstructive pulmonary disease(copd) and heart failure (hf). interestingly there are drugs available which block the actions of gdf-8 on muscle cells which has been shown in animals to result in increased muscle size. a related protein called gdf-15 is found in elevated levels in patients pah, and is linked to prognosis. our preliminary data suggests that gdf-15 can also directly influence muscle size in a number of situations. we aim to investigate the role of gdf-15 and related molecules in the development of muscle weakness in patients with pah. we will do this by measuring certain markers of muscle weakness and taking blood and muscle samples in patients and controls. we will then compare the levels of gdf-15 in these tissues in those with and without muscle wasting. we hope this work will lead to a greater understanding of the role of gdf-15 in the development of muscle weakness in patients with pah. gdf-15 levels may be important in allowing us to define which patients have muscle weakness. in the future we aim to perform a clinical trial of drugs which block the actions of gdf-15.


Eligibility criteria:
inclusion criteria: * patients with pulmonary arterial hypertension with new york heart association stage ii - iii disease will be eligible for recruitment in the patient portion of the trial. interested healthy age matched volunteers will also be recruited. exclusion criteria: * patients and volunteers will be excluded if they have significant co-morbidities including other cardiorespiratory disease, metabolic abnormalities including diabetes or thyroid disorders. they will be excluded if they cannot safely exercise and perform a six minute walk test or if they are wheelchair bound.

Keywords: muscle weakness pulmonary arterial hypertension transforming growth factor beta growth and differentiation factor 15
bilateral laryngeal paralysis reinnervation

Conditions: Vocal Cord Paralysis

Summary: bilateral laryngeal reinnervation induces a rise in laryngeal resistance and speech alteration. the aim of this study is to propose laryngeal reinnervation by a phrenic nerve root to patients with bilateral laryngeal paralysis.


Eligibility criteria:
inclusion criteria: * bilateral laryngeal paralysis without any amelioration for six months exclusion criteria: * laryngeal paralysis more than 3 years * arycricoideus ankylostosis * pacemaker * pregnancy

Keywords: bilateral vocal cord paralysis reinnervation phrenic nerve
effects of red ginseng on gastrointestinal symptoms and microbiota after surgery for gastrointestinal cancer

Conditions: Stomach Cancer; Pancreatobiliary Cancer; Colorectal Cancer

Summary: after surgery for gastrointestinal cancer (stomach cancer, pancreaticobiliary cancer, colorectal cancer), many patients experiences various symptoms such as weight loss, diarrhea, constipation and excessive gas due to structural and functional changes in the gastrointestinal tract. these changes are thought to be influenced by alterations in gut microbiota following surgery, but prospective studies are still lacking. it is anticipated that the prebiotic effects of red ginseng may lead to positive changes in total gut bactera after gastrointestinal caner surgery. through this study, investigators aim to investigate the impact of red ginseng consumption on gut microbiota composition, gastrointestinal symptoms, and nutritional status improvement following surgery for gastrointestinal cancer.


Eligibility criteria:
inclusion criteria: 1. pathologically diagnosed with gastrointestinal cancers (stomach cancer, pancreatobiliary cancer, colorectal cancer) prior to surgery. 2. clinically staged and anticipated to not receive adjuvant chemotherapy after surgery. 3. eligible for complete surgical resection (r0 resection). 4. asa (american society of anesthesiologists) score of 3 or below. 5. intereseted in health functional foods. 6. not consumed probiotics or prebiotics for at least three months prior to study enrollment. 7. willing to refrain from consuming additional probiotics or prebiotics during the study period, apart from the provided red ginseng tablets. exclusion criteria: 1. patients aged 80 years or older. 2. patients who received neoadjuvant therapy before surgery. 3. patients with underlying gastrointestinal disorders (e.g., inflammatory bowel disease, ulcerative colitis, crohn's disease, galactose intolerance, lactase deficiency, glucose-galactose malabsorption, short bowel syndrome, other hereditary gastrointestinal diseases, and autoimmune diseases). 4. patients unable to orally consume red ginseng tablets. 5. patients with a history of previous abdominal organ surgery, radiation therapy, or chemotherapy. 6. patients with intestinal obstruction before surgery. 7. patients regularly taking probiotic or prebiotic supplements. 8. patients requiring formation of an ileostomy after surgery. 9. patients with uncontrolled diabetes that may affect gastrointestinal function. 10. patients with underlying conditions such as liver failure or renal failure. 11. patients allergic to red ginseng. 12. patients who received more than two weeks of antibiotic treatment during hospitalization.
use of direct oral anticoagulants in uk

Conditions: Stroke

Summary: many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. it is important to prescribe the correct dose of blood thinners to the right patients to ensure the treatment works however avoiding complications. in the recent years, new blood thinners have been available; they require less laboratory tests and fewer visits to a doctor compared to older therapies. this study will look at how the general practitioners in the uk prescribe blood thinners according to the instructions given by the product manufacturer. we will use primary care data that is routinely collected by the general practitioners about their patients but without any possibility to identify individual patients. the results will help us to understand the magnitude of deviation from instructions in order to ensure that the patients benefit from the treatment.


Eligibility criteria:
inclusion criteria: * all patients aged \>= 18 years with at least one year of enrollment with the primary care practice and one year since first health contact recorded in the database thin(the health improvement network) or cprd(clinical practice research datalink) prior to index prescription date will be included. * patients with first prescription of doacs (rivaroxaban, dabigatran, apixaban) during the study period. * diagnosis nvaf (any time prior index date or within the 2 weeks after the index date) exclusion criteria: * patients having the history of valvular replacement or mitral stenosis (prior to index date or 2 weeks after index-date) * patients who have any record of being prescribed their index drug prior to the enrolment period or who qualify as members of more than one cohort on the same day.

Keywords: stroke prevention in nvaf patients
compression therapy as a prophylactic method against cipn: a prospective self-controlled trial

Conditions: Nasopharyngeal Carcinoma; CIPN - Chemotherapy-Induced Peripheral Neuropathy

Summary: this is a single-center, self-controlled, evaluator-blinded prospective study, which applies pressurized gloves and foot caps to prevent paclitaxel-induced peripheral neuropathy in patients with nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * age range from 18 to 70 * ecog physical status score: 0-2 * newly diagnosed patients who have not received antitumor therapy * nasopharyngeal carcinoma confirmed by pathology * paclitaxel is included in the chemotherapy regimen * laboratory examination results within one week before enrollment should meet the following conditions: neutrophils (anc) ≥1.5×109/l, platelets (plt) ≥80×109/l, total bilirubin (tbi) ≤1.5× upper limit of normal value (2mg/ dl), alt and ast ≤2× upper limit of normal value * patients voluntarily participate and provide written informed consent exclusion criteria: * patients with peripheral neuropathy, hand-foot syndrome, and dermatomyositis * patients with missing fingers or toes * patients with raynaud's syndrome and peripheral vascular ischemia * pregnant or lactating women * those considered unsuitable for inclusion by the researcher

Keywords: paclitaxel compression therapy